Sökning: onr:"swepub:oai:lup.lub.lu.se:7650437d-c255-4d84-8bd6-acc296335808" >
Long-Term Safety, T...
Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study
-
Bray, George A. (författare)
-
Edelstein, Sharon L. (författare)
-
Crandall, Jill P. (författare)
-
visa fler...
-
Aroda, Vanita R. (författare)
-
- Franks, Paul (författare)
- Lund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups
-
Fujimoto, Wilfred (författare)
-
Horton, Edward (författare)
-
Jeffries, Susan (författare)
-
Montez, Maria (författare)
-
Mudaliar, Sunder (författare)
-
Pi-Sunyer, F. Xavier (författare)
-
White, Neil H. (författare)
-
Knowler, William C. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2012-03-13
- 2012
- Engelska.
-
Ingår i: Diabetes Care. - : American Diabetes Association. - 1935-5548 .- 0149-5992. ; 35:4, s. 731-737
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://care.diabete...
-
https://lup.lub.lu.s...
-
https://doi.org/10.2...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVE-Metformin produced weight loss and delayed or prevented diabetes in the Diabetes Prevention Program (DPP). We examined its long-term safety and tolerability along with weight loss, and change in waist circumference during the DPP and its long-term follow-up. RESEARCH DESIGN AND METHODS-The randomized double-blind clinical trial of metformin or placebo followed by a 7-8-year open-label extension and analysis of adverse events, tolerability, and the effect of adherence on change in weight and waist circumference. RESULTS-No significant safety issues were identified. Gastrointestinal symptoms were more common in metformin than placebo participants and declined over time. During the DPP, average hemoglobin and hematocrit levels were slightly lower in the metformin group than in the placebo group. Decreases in hemoglobin and hematocrit in the metformin group occurred during the first year following randomization, with no further changes observed over time. During the DPP, metformin participants had reduced body weight and waist circumference compared with placebo (weight by 2.06 +/- 5.65% vs. 0.02 +/- 5.52%, P < 0.001, and waist circumference by 2.13 +/- 7.06 cm vs. 0.79 +/- 6.54 cm, P < 0.001 in metformin vs. placebo, respectively). The magnitude of weight loss during the 2-year double-blind period was directly related to adherence (P < 0.001). Throughout the unblinded follow-up, weight loss remained significantly greater in the metformin group than in the placebo group (2.0 vs. 0.2%, P < 0.001), and this was related to the degree of continuing metformin adherence (P < 0.001). CONCLUSIONS-Metformin used for diabetes prevention is safe and well tolerated. Weight loss is related to adherence to metformin and is durable for at least 10 years of treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bray, George A.
-
Edelstein, Sharo ...
-
Crandall, Jill P ...
-
Aroda, Vanita R.
-
Franks, Paul
-
Fujimoto, Wilfre ...
-
visa fler...
-
Horton, Edward
-
Jeffries, Susan
-
Montez, Maria
-
Mudaliar, Sunder
-
Pi-Sunyer, F. Xa ...
-
White, Neil H.
-
Knowler, William ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Diabetes Care
- Av lärosätet
-
Lunds universitet